Rubius Therapeutics Inc (5RT.SG)
| Previous close | 0.0157 |
| Open | 0.0157 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0157 - 0.0157 |
| 52-week range | 0.0060 - 1.4100 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 07 Nov 2023 - 13 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireGolden Arrow Drills 64m of 0.86% Cu, 0.20g/t Au, 196g/t Co & 25.9% Fe at central Rincones Target, San Pietro Project, Chile
Golden Arrow Resources Corporation (TSXV: GRG) (FSE: G6A) (OTCQB: GARWF), ("Golden Arrow" or the "Company") is pleased to report results for the remaining six holes of the 4,000 metre Phase 1 drilling program at the Company's flagship San Pietro Iron-Copper-Gold-Cobalt Project in Chile. All six holes reported herein are from the Rincones target, which is the most advanced target and the focus of the Company's first resource delineation plan for the project.
GlobeNewswireRubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes
Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to ma
